Strata Critical Medical (SRTA) Revenue (2020 - 2026)

Strata Critical Medical (SRTA) has 7 years of Revenue data on file, last reported at $67.4 million in Q1 2026.

• Quarterly Revenue rose 87.45% year-over-year to $67.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254.3 million (up 44.19% YoY) and the FY2025 annual result came in at $197.1 million, up 34.28% from the prior year.
• Revenue climbed to $67.4 million in Q1 2026 per SRTA's latest filing, from $66.8 million in the prior quarter.
• Across five years, Revenue topped out at $71.4 million in Q3 2023 and bottomed at $26.6 million in Q1 2022.
• The 5-year median for Revenue is $49.3 million (2025), against an average of $51.3 million.
• The widest annual swing landed in 2022, when Revenue jumped 187.18%; it then plunged 49.52% in 2024.
• Tracing SRTA's Revenue over 5 years: stood at $35.6 million in 2022, then soared by 33.24% to $47.5 million in 2023, then retreated by 23.36% to $36.4 million in 2024, then jumped by 83.54% to $66.8 million in 2025, then gained by 0.89% to $67.4 million in 2026.
• Per Business Quant, the three latest SRTA Revenue figures stand at $67.4 million (Q1 2026), $66.8 million (Q4 2025), and $49.3 million (Q3 2025).

Peer Comparison